Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- HC Wainwright & Co. analyst Ed Arce initiated coverage on MetaVia MTVA with a Buy rating and announced a price target of $12. MetaVia shares closed at $1.76 on Friday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions Inc. EBS with a Buy rating and announced a price target of $15. Emergent BioSolutions shares closed at $8.27 on Friday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on Nuvalent, Inc. NUVL with a Buy rating and announced a price target of $110. Nuvalent shares closed at $80.30 on Friday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Douglas Tsao initiated coverage on Arcutis Biotherapeutics, Inc. ARQT with a Buy rating and announced a price target of $19. Arcutis Biotherapeutics shares closed at $14.30 on Friday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Edward White initiated coverage on Artiva Biotherapeutics, Inc. ARTV with a Buy rating and announced a price target of $20. Artiva Biotherapeutics shares closed at $10.64 on Friday. See how other analysts view this stock.
Considering buying NUVL stock? Here’s what analysts think:
Trending Investment Opportunities
Advertisement
Read This Next:
Loading...
Loading...
ARQTArcutis Biotherapeutics Inc
$14.25-2.26%
Edge Rankings
Momentum
85.71
Growth
N/A
Quality
N/A
Value
27.69
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|